OncoMatch/Clinical Trials/NCT05528133
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
Is NCT05528133 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for triple negative breast cancer.
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) in people with triple negative (HER2 negative, hormone receptor negative) breast cancer undergoing breast conservation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (must NOT demonstrate overexpression by IHC or ISH as defined by ASCO/CAP)
a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines
Required: ESR1 expression <10% by IHC (<10%)
a breast cancer must express (<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines
Required: PR (PGR) expression <10% by IHC (<10%)
a breast cancer must express (<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines
Prior therapy
Must have received: breast conservation therapy
Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Morton Plant Hospital - Baycare Health System · Clearwater, Florida
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify